Last updated on July 4, 2024
PharmEasy Unlisted Share Description – PharmEasy-parent API Holdings is India’s largest digital healthcare platform (based on GMV of products and services sold for the year ended 31 March 2021) which operates an integrated, end-to-end business that aims to provide solutions for the healthcare needs of consumers across the following critical stages-
A. providing digital tools and information on illness and wellness
B. offering teleconsultation
C. offering diagnostics and radiology tests
D. delivering treatment protocols including products and devices
API Holdings’ custom-built technology platform aims to provide each stakeholder with the healthcare value-chain benefits of an interconnected network. It works closely with and builds services for consumers, pharmaceutical companies, wholesalers, pharmacies, hospitals, doctors and clinics, and diagnostic labs. Its growing nationwide presence, the connected ecosystem approach, and multiple synergistic offerings have enabled it to build relationships across the healthcare value chain including wholesalers, chemists, consultants, consumers, and companies.
What is PharmEasy?
PharmEasy is a consumer healthcare “super app” that provides consumers with on-demand, home-delivered access to a wide range of prescription, OTC pharmaceuticals, other consumer healthcare products, comprehensive diagnostic test services, and teleconsultations thereby serving their healthcare needs.
Read Also: Sterlite Power Unlisted Shares
Products & Services of the PharmEasy
- Prescription/OTC pharmaceuticals
- Consumer healthcare products
- Comprehensive diagnostic test services
- Teleconsultations
PharmEasy Subsidiaries Companies
- Docon Technologies Private Ltd.
- Ascent Wellness and Pharma Solutions Private Ltd.
- Threpsi Solutions Private Ltd.
- ARZT and Health Private Ltd.
- Ayro Retail Solutions Private Ltd.
- Instinct Innovation Private Ltd
- Eastern Agencies Healthcare Private Ltd.
- Thyrocare Technologies Limited
- AKP Healthcare Private Ltd.
- Venkatesh Medico Private Ltd.
Key Highlights –
- The company is expanding its products business in Semi Urban + Rural Markets across India
- Deeper penetration into Tier-2 & Tier 3 cities
- 40%+ GMV on distribution to retailer business contributed by Tier 2 cities and semi-urban and rural areas
- 20%+ of Retailio 1P’s GMV contributed by tier 2 cities and semi-urban and rural areas
- 20%+ of Aknamed’s GMV contributed by tier 2 cities and semi-urban and rural areas
- Served 2,300+ pin codes with its own logistics network and ~15,000+ pin codes through 3PL partners
Read Also: Biggest Unlisted Companies in India
API Holdings Board of Directors
- Mr. Siddharth Shah, MD & CEO
- Mr. Harsh Parekh, Whole-time Director
- Mr. Dharmil Sheth, Whole-time Director
- Aditya Puri, Chairman, Non-Executive Director
- Deepak Vaidya, Independent, Non-Executive Director
- Ankur Thadani, Non-Executive Director
- Ashutosh Sharma, Non-Executive Director
- Vineeta Rai, Independent, Non-Executive Director
- Dr. Jaydeep Tank, Independent, Non-Executive Director
- Mr. Subramaniam Somasundaram, Independent, Non-Executive Director
PharmEasy Unlisted Share Details
| Name | PharmEasy Unlisted Share Details |
| Face Value | INR 1 per share |
| ISIN Code | INE0DJ201029 |
| Lot Size | 1,000 shares |
| Demat Status | NSDL, CDSL |
| PharmEasy Unlisted Share Price | INR 10 per share |
| Market Cap | INR 14,520 crore |
| Total number of shares | 1,452 crore shares |
| Website | www.pharmeasy.in |
PharmEasy Unlisted Share Details – Shareholding Pattern
Details of shareholders holding of a class of equity shares in the Company:
| Shareholder Name | % to Holding | No. of shares |
| Naspers Ventures B. V. | 12.04 | 813,316,570 |
| MacRitchie Investments Pte. Ltd. | 10.84 | 732,516,290 |
| TPG Growth V SF Markets Pte. Ltd | 6.65 | 449,492,340 |
| Evermed Holdings Pte. Ltd. | 6.45 | 396,033,000 |
| Siddarth Shah | 1.32 | 89,176,340 |
| Dharmil Sheth | 0.30 | 18,269,329 |
| Harsh Parekh | 0.28 | 17,037,456 |
PharmEasy Unlisted Share Details – Financial Metrics
| Particulars | FY 2021 | FY 2022 | FY 2023 |
| Revenue | 2,335.27 | 5,728.82 | 6,705.26 |
| Expenses | 2,980.93 | 8,491.59 | 8,974.01 |
| Net income | (641.34) | (3,992.50) | (2,277.30) |
| Margin (%) | (27.46) | (69.69) | (33.96) |
| OPM (%) | (24.38) | (39.00) | (23.40) |
| EBITDA (%) | (24.37) | (40.18) | (23.40) |
| EPS | (2.67) | (7.28) | (1.56) |
Read Also: Best IPOs That Doubled Investors’ Money
PharmEasy Annual Reports
PharmEasy Annual Report FY 2021 – 2022
PharmEasy Draft Red Herring Prospectus
PharmEasy Unlisted Share Peer Comparison
| Company | 3-yr Sales CAGR (%) | PE Ratio | Net Margin (%) | MCap (INR crore) |
| PharmEasy (API Holdings) | 115.71 | – | (33.96) | 14,520 |
| Apollo Hospitals (Apollo Pharmacy) | 21.8 | 100.0 | 4.91 | 89,738 |
PharmEasy Unlisted Share FAQs
Is it safe to purchase unlisted shares in India?
While there are risks associated with unlisted shares, purchases made from credible brokers and after conducting due diligence considerably lower these risks.
What is PharmEasy unlisted share price?
PharmEasy unlisted stock price in July 2024 is INR 10 per share. Shares are purchased in lots of 1,000 shares.
Who determines PharmEasy share price?
The unlisted share price is determined by various factors including recent transaction price, supply and demand, valuation in the latest funding round, profitability, and return ratios.
When is PharmEasy IPO planned?
PharmEasy’s parent API Holdings has also delayed internal plans for a potential IPO to 2025, the people privy to the goings-on at the company said on condition of anonymity.
